Skip to content
The Nexus
DossierENTITY

Ceres Brain Therapeutics

Coverage of Ceres Brain Therapeutics in the Nexus archive.

Earliest in view: Jul 31 · 09:00 UTCMost recent: Jul 31 · 09:00 UTC
Co-mentioned in this coverage
Kris DeVaultperson1Brody DeVaultperson1Montanaplace1Creatine transporter deficiencytopic1right to try lawtopic1phase I clinical trialtopic1nasal spraytopic1
Recent coverage
  • HEALTHJul 31 · 09:00 UTCMIT TECHNOLOGY REVIEW
    Montana’s new “right to try” law can’t come soon enough for some

    Kris DeVault's son Brody has creatine transporter deficiency, a rare genetic condition with no cure. A French biotech company, Ceres Brain Therapeutics, is developing an experimental nasal spray drug for the condition, currently in early testing phases. Montana's new 'right to try' law may help families like the DeVaults access unapproved treatments.

Ceres Brain Therapeutics · Dossier · The Nexus